SKY01
Solid Tumors (Pancreatic, TNBC, Lung, Colorectal)
PreclinicalActive
Key Facts
Indication
Solid Tumors (Pancreatic, TNBC, Lung, Colorectal)
Phase
Preclinical
Status
Active
Company
About SEEKYO Therapeutics
Seekyo Therapeutics, founded in 2018 and based in Paris, is pioneering a new paradigm in oncology with its Tumor Activated Therapy™ platform. This approach targets functional proteins selectively produced within the tumor microenvironment, enabling localized activation of therapeutic agents to overcome tumor heterogeneity and reduce systemic toxicity. The company's lead program, SKY01, has demonstrated efficacy and safety in animal models across multiple difficult-to-treat solid tumors, positioning Seekyo to address a significant unmet need in oncology. It operates as a private, preclinical-stage biotech seeking partnerships to advance its internal pipeline and platform.
View full company profile